CN101193643A - 端粒酶阳性细胞中端粒长度的调节和癌症治疗 - Google Patents

端粒酶阳性细胞中端粒长度的调节和癌症治疗 Download PDF

Info

Publication number
CN101193643A
CN101193643A CNA200680015221XA CN200680015221A CN101193643A CN 101193643 A CN101193643 A CN 101193643A CN A200680015221X A CNA200680015221X A CN A200680015221XA CN 200680015221 A CN200680015221 A CN 200680015221A CN 101193643 A CN101193643 A CN 101193643A
Authority
CN
China
Prior art keywords
cancer
cells
cancer cells
telomerase
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200680015221XA
Other languages
English (en)
Chinese (zh)
Inventor
I·E·博恩达尔耶夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALT solutions Inc
Original Assignee
ALT solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALT solutions Inc filed Critical ALT solutions Inc
Priority to CN201510092529.5A priority Critical patent/CN104997783A/zh
Publication of CN101193643A publication Critical patent/CN101193643A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA200680015221XA 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗 Pending CN101193643A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510092529.5A CN104997783A (zh) 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66510505P 2005-03-25 2005-03-25
US60/665,105 2005-03-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510092529.5A Division CN104997783A (zh) 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗

Publications (1)

Publication Number Publication Date
CN101193643A true CN101193643A (zh) 2008-06-04

Family

ID=37053967

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200680015221XA Pending CN101193643A (zh) 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗
CN201510092529.5A Pending CN104997783A (zh) 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510092529.5A Pending CN104997783A (zh) 2005-03-25 2006-03-27 端粒酶阳性细胞中端粒长度的调节和癌症治疗

Country Status (6)

Country Link
US (5) US7741296B2 (enExample)
EP (1) EP1868615A4 (enExample)
JP (2) JP2008536822A (enExample)
CN (2) CN101193643A (enExample)
CA (1) CA2602562C (enExample)
WO (1) WO2006104975A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102660650A (zh) * 2012-05-25 2012-09-12 云南路易斯中药现代化工程技术研究中心 一种实时定量pcr测量样品中染色体端粒平均长度的绝对值的试剂盒及应用
CN111494629A (zh) * 2012-11-30 2020-08-07 美国杰龙生物医药公司 用端粒酶抑制剂治疗细胞增殖性病症的诊断标志物
CN112168829A (zh) * 2020-09-24 2021-01-05 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
WO2006125166A2 (en) * 2005-05-18 2006-11-23 Alt Solutions, Inc. Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
WO2007106561A2 (en) * 2006-03-14 2007-09-20 Alt Solutions, Inc. Prevention and treatment of cancer and other diseases
ES2874774T3 (es) 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
US9795242B2 (en) 2013-02-14 2017-10-24 Cirkul, Inc. Additive delivery systems and containers
WO2016081925A1 (en) 2014-11-21 2016-05-26 Samsara Bottle System, Inc. Adjustable additive cartridge systems
US10888826B2 (en) 2014-11-21 2021-01-12 Cirkul, Inc. Adjustable additive cartridge systems and methods
EP3753563A1 (en) * 2019-06-20 2020-12-23 Helmholtz-Zentrum für Infektionsforschung GmbH Anti-herpesvirus guanosine analogue for the inhibition of basal autophagy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
WO1997021452A2 (en) * 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
AU780815B2 (en) * 1999-06-23 2005-04-21 University Of Vermont And State Agricultural College, The Methods and products for manipulating uncoupling protein expression
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102660650A (zh) * 2012-05-25 2012-09-12 云南路易斯中药现代化工程技术研究中心 一种实时定量pcr测量样品中染色体端粒平均长度的绝对值的试剂盒及应用
CN111494629A (zh) * 2012-11-30 2020-08-07 美国杰龙生物医药公司 用端粒酶抑制剂治疗细胞增殖性病症的诊断标志物
CN112168829A (zh) * 2020-09-24 2021-01-05 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Also Published As

Publication number Publication date
JP2008536822A (ja) 2008-09-11
US8580753B2 (en) 2013-11-12
JP2013224953A (ja) 2013-10-31
US8097595B2 (en) 2012-01-17
US20120107863A1 (en) 2012-05-03
WO2006104975A2 (en) 2006-10-05
EP1868615A4 (en) 2012-06-27
US7741296B2 (en) 2010-06-22
US20140065072A1 (en) 2014-03-06
EP1868615A2 (en) 2007-12-26
WO2006104975A3 (en) 2007-12-27
US20100227832A1 (en) 2010-09-09
CA2602562A1 (en) 2006-10-05
CA2602562C (en) 2015-07-07
CN104997783A (zh) 2015-10-28
US20160000937A1 (en) 2016-01-07
US20090023677A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
US8580753B2 (en) Modulation of telomere length in telomerase positive cells and cancer therapy
US9078901B2 (en) Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
Röth et al. Imetelstat (GRN163L)-telomerase-based cancer therapy
KR102294819B1 (ko) 골증식성 장애 및 골증식성 신생물의 치료를 위한 텔로메라제 저해제들의 용도
D'Alimonte et al. Adenosine A1 receptor stimulation enhances osteogenic differentiation of human dental pulp-derived mesenchymal stem cells via WNT signaling
EP3781689A1 (en) Synthetic rig-i-like receptor agonists
EP2623105A2 (en) Modulation of line-1 reverse transcriptase
Agrawal et al. Recent patents on anti-telomerase cancer therapy
JP2016175917A (ja) 癌およびその他の疾患の予防および治療
Chen et al. The role of nicotinamide adenine dinucleotide in the pathogenesis of rheumatoid arthritis: potential implications for treatment
Davison Imbalanced nucleotide metabolism sensitises triple negative breast cancer cell lines to standard of care chemotherapies
Chen et al. Methods for modulation and inhibition of telomerase
Tamakawa Combination chemotherapy with telomerase inhibitors and genotoxic compounds against breast and colorectal cancers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080604